Buamah P K, Johnson P, Skillen A W
Department of Clinical Biochemistry, Thanet District General Hospital, Margate.
Br J Urol. 1988 Dec;62(6):581-3. doi: 10.1111/j.1464-410x.1988.tb04430.x.
The clinical usefulness of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) activity measurements has been compared in 45 patients with benign prostatic hyperplasia (BPH) and 132 patients with prostatic carcinoma (PC), 21 of whom had metastatic disease (MPC) and 111 of whom had intracapsular cancer. No BPH patient had increased PAP but 47% had increased PSA. Of the PC patients only 27% had increased PAP and 70% increased PSA. All of the MPC patients had increased PSA but only 62% had increased PAP. Increased PAP was found only in MPC but increased PSA was also found in BPH. In identifying PC, the predictive value of an increased PSA concentration is 83% and an increased PAP activity is 100%. On the other hand, the predictive value of a normal PSA concentration is 51% and of a normal PAP activity only 34%. As the PAP test is much less efficient than the PSA test, it should be discontinued.
对45例良性前列腺增生（BPH）患者和132例前列腺癌（PC）患者进行了比较，评估前列腺特异性抗原（PSA）和前列腺酸性磷酸酶（PAP）活性测量的临床实用性。其中，21例前列腺癌患者有转移病灶（MPC），111例为包膜内癌。没有BPH患者的PAP升高，但47%的患者PSA升高。在PC患者中，只有27%的患者PAP升高，70%的患者PSA升高。所有MPC患者的PSA都升高，但只有62%的患者PAP升高。仅在MPC患者中发现PAP升高，但在BPH患者中也发现PSA升高。在识别PC时，PSA浓度升高的预测价值为83%，PAP活性升高的预测价值为100%。另一方面，PSA浓度正常的预测价值为51%，PAP活性正常的预测价值仅为34%。由于PAP检测的效率远低于PSA检测，因此应停止使用。
